$6.23 Billion Market Opportunity Via Exclusive Global License to Manufacture and Sell Emesyl OTC Nausea Relief Product by Caring Brands Inc. (Nasdaq: CABR)

• Marketing a Portfolio of Unique, Patented and Clinically Validated Products for Skin and Hair Growth.

• Plans to Launch 5 Products Over the Next 2 Years in Addition to In-Licensing Additional Products.

• Management has a Successful Track Record of Strategic Acquisitions, Rapid Product Development, IP Development and Product Licensing.

• Revenues From Sales of Hair Enzyme Booster for Hair Loss, and Photocil for Psoriasis and Vitiligo via Sales in the US and Licensees in India.

• Additional Product Opportunities Include Treatment of Eczema and a Sunscreen That Prevents Jellyfish Stings.

• Exclusive Global License with Itonis, Inc. to Manufacture and Market Emesyl Over-The-Counter Nausea Relief Product.

• Agreement Includes Royalty Structure Based on Future Net Sales Plus Potential for CABR to Earn Equity in Itonis, Inc. Tied to Revenue Milestones.

• Global Market for Nausea Treatment and Related Therapies Projected to Exceed $6.23 Billion USD.

• $4 Million Public Offering Completed with Uplisting to NASDAQ.

Caring Brands Inc. (Nasdaq: CABR) has a growing portfolio of unique, patented, and clinically validated products for skin and hair growth. CABR intends to launch a total of 5 products over the next 2 years in addition to in-licensing additional products. CABR management has a successful track record of strategic acquisitions, rapid product development, IP development and product licensing. Revenues from the sales of Hair Enzyme Booster for the treatment of hair loss, and Photocil for the treatment of psoriasis and vitiligo, are currently being generated by direct sales in the US and licensees in India. Additional product opportunities include CB-101 for the treatment of eczema, NoStingz, a sunscreen that prevents jellyfish stings.

Exclusive Global License with Itonis to Manufacture and Market Emesyl OTC Nausea Relief Product

On January 5th CABR announced that it has entered into an exclusive worldwide license agreement with Itonis Inc. to manufacture, market, and distribute Emesyl, Itonis’s over-the-counter (OTC) nausea relief product. The agreement provides CABR with full rights to commercialize Emesyl and to oversee all manufacturing activities associated with the product.

CABR will assume responsibility for product manufacturing, marketing, sales strategy, and global distribution. Itonis will provide technical information, product formulation data, historical sales information, and intellectual property details to support the CABR commercial launch and ongoing development efforts.

According to QY Research, the global market for nausea treatment and related therapies is projected to exceed USD 6.23 billion in 2025, underscoring the broader commercial context for the Emesyl license.

The agreement includes a royalty structure based on future net sales, along with the potential for CABR to earn equity in Itonis tied to revenue milestones. CABR expects to provide further updates on product timelines, manufacturing progress, and commercial rollout as these initiatives advance.

Glynn Wilson, CEO CABR, said, “Securing the exclusive rights to Emesyl marks an important milestone for Caring Brands as we expand our health and wellness portfolio. Emesyl brings a recognized product with real commercial potential, and we look forward to revitalizing and scaling its market presence. This agreement aligns perfectly with our long‑term strategy for OTC products, and we are excited to share more about our upcoming plans in the months ahead.”

CABR Closing of $4,000,000 Million Uplisting to Nasdaq

On November 14th CABR announced the closing of its underwritten U.S. public offering of 1,000,000 shares of common stock at a public offering price of $4.00 per share for aggregate gross proceeds of approximately US $4,000,000, prior to deducting underwriting discounts and offering expenses. The shares of common stock commenced trading on the Nasdaq Capital Markets on November 13, 2025.

In addition, CABR granted the underwriter a 45-day option to purchase up to an additional 150,000 shares at the public offering price, less the underwriting discounts and commissions.

CABR intends to use the net proceeds received from this offering for general and working capital purposes, including but not limited to marketing and sales of its proprietary products, and for the repayment of certain debt. D. Boral Capital LLC acted as the sole underwriter in connection with this offering.

For more information on CABR visit: www.caringbrands.com

DISCLAIMER: https://corporateads.com/disclaimer/

Disclosure listed on the CorporateAds website